YD Bio Limited Ordinary Shares
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Ethan Shen
- Full Time Employees
- 14
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- No. 3, Xingnan St. Taipei TP Taiwan, Province of China 115001
- IPO Date
- Aug 29, 2025
- CIK
- 0002011674
- Website
- ydesgroup.com
- Similar Companies
- Business
- YD Bio Limited is a biotechnology company specializing in blood-based cancer detection and the development of stem cell- and exosome-based therapeutics targeting diseases with high unmet medical needs. Its core product portfolio includes non-invasive DNA methylation analysis for early cancer detection, treatment monitoring, and recurrence tracking, with licensed technologies for pancreatic and breast cancer detection; innovative ophthalmologic products such as exosome-based therapies, contact lenses, and artificial tears addressing dry eye syndrome and other ocular diseases; and supplying clinical trial drugs and nutritional supplements. The company operates primarily in Taiwan and has expanded into the U.S., Europe, and Asia-Pacific markets via strategic licensing agreements and independent laboratory establishments. Founded in 2013 and headquartered in Taipei, Taiwan, YD Bio Limited recently completed a business combination with Breeze Holdings Acquisition Corp, resulting in its listing on the Nasdaq Global Market under the ticker YDES in August 2025. This transaction facilitated $11.5 million in financing aimed at accelerating innovation, production scale, and commercialization of its cutting-edge diagnostics and therapy platforms. Key recent developments include exclusive licensing agreements with EG BioMed for DNA methylation cancer detection technologies, with an independent U.S. lab dedicated to pancreatic cancer early detection, and ongoing efforts to launch breast cancer detection assays across global markets. Additionally, the company secured patents and market authorization supporting its exosome therapeutics for ocular conditions through partnerships with 3D Global Biotech, including plans to initiate clinical trials for novel exosome-based contact lenses and artificial tears by 2027. YD Bio also serves as a clinical testing drug supplier for major pharmaceutical firms, such as Novartis, enhancing its market reach and operational breadth. YD Bio Limited's business model focuses on transforming innovative biomedical technologies into commercially viable clinical diagnostics and regenerative medicines, supported by multi-decade exclusive licensing rights and a robust intellectual property portfolio. The company’s strategic focus spans oncology diagnostics, regenerative ophthalmology, and clinical trial support, positioning it as an emerging leader with strong growth potential in diverse healthcare sectors globally. Its mission is to improve patient outcomes through breakthrough scientific innovation and precision medicine across fast-growing healthcare markets. This comprehensive engagement with advanced diagnostics, regenerative therapies, and pharmaceutical collaborations underscores YD Bio Limited’s commitment to pioneering solutions for early cancer detection and complex disease management, while expanding commercial and clinical trial operations worldwide. The company is led by Chairman Dr. Ethan Shen, a biomedical expert with over 30 years of experience driving research and development initiatives.
Company News
YD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness Programs
YD Bio Limited (NASDAQ:YDES) Sees Significant Increase in Short Interest
YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment
YD Bio (NASDAQ:YDES) Shares Down 4.4% – Here’s Why
YD Bio Limited (NASDAQ:YDES) Sees Large Increase in Short Interest
YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026
YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute
Head-To-Head Comparison: YD Bio (NASDAQ:YDES) versus Arbutus Biopharma (NASDAQ:ABUS)
YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada
YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services
YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations
YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations
YD Bio Limited Reports Full Year 2025 Financial Results
YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States
YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem
YD Bio (NASDAQ:YDES) Shares Gap Up – Here’s What Happened
YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform
YD Bio (NASDAQ:YDES) Shares Down 9.9% – Here’s What Happened
YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy
YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development